Abstract
Lactobacillus casei strain Shirota was selected as a bacterial carrier for the development of live mucosal vaccines against coronavirus. A 75 kDa fragment of transmissible gastroenteritis coronavirus (TGEV) spike glycoprotein S was used as the model coronavirus antigen. The S glycoprotein was cloned into a Lactobacillus/E. coli shuttle vector (pLP500) where expression and secretion of the glycoprotein S from the recombinant lactobacilli was detected via immunoblotting. Oral immunization of BALB/c mice with recombinant LcS that constitutively expresses the 75 kDa fragment of the glycoprotein S, induced both local mucosal and systemic immune responses against TGEV. Maximum titers of IgG (8.38+/-0.19 ng/ml of serum) and IgA (64.82+/-2.9 ng/ml of intestinal water) were attained 32 days post oral inturbation. The induced antibodies demonstrated neutralizing effects on TGEV infection.
MeSH terms
-
Administration, Oral
-
Animals
-
Antibodies, Viral / blood
-
Antibody Formation
-
Disease Models, Animal
-
Female
-
Gastroenteritis, Transmissible, of Swine / prevention & control*
-
Immunity, Mucosal
-
Immunoglobulin A / analysis
-
Immunoglobulin G / blood
-
Lacticaseibacillus casei / genetics
-
Lacticaseibacillus casei / immunology*
-
Lacticaseibacillus casei / metabolism
-
Membrane Glycoproteins / genetics
-
Membrane Glycoproteins / immunology*
-
Membrane Glycoproteins / metabolism
-
Mice
-
Mice, Inbred BALB C
-
Neutralization Tests
-
Spike Glycoprotein, Coronavirus
-
Transmissible gastroenteritis virus / genetics
-
Transmissible gastroenteritis virus / immunology*
-
Vaccines, Synthetic / genetics
-
Vaccines, Synthetic / immunology
-
Vaccines, Synthetic / metabolism
-
Viral Envelope Proteins / genetics
-
Viral Envelope Proteins / immunology*
-
Viral Envelope Proteins / metabolism
Substances
-
Antibodies, Viral
-
Immunoglobulin A
-
Immunoglobulin G
-
Membrane Glycoproteins
-
Spike Glycoprotein, Coronavirus
-
Vaccines, Synthetic
-
Viral Envelope Proteins